ReviewFrontiers in immunology2026
Research progress on targeted regulatory proteins in the prevention and treatment of atherosclerosis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis (AS) is a chronic inflammatory disease characterized by lipid metabolic dysregulation and vascular cell phenotypic switching. Its progression is governed by intricate interactions between immune and vascular cells within multi-layered molecular networks. This review synthesizes recent evidence on the specific roles of key regulatory proteins in atherogenesis. We first examine how epigenetic modifiers, notably histone deacetylases, Sirtuins, EZH2, and TET2, remodel chromatin to activate pro-inflammatory gene programs. Subsequently, we delineate how critical transcription factors, such as KLFs, PPARs, Nrf2, and BACH1, couple metabolic homeostasis with anti-inflammatory responses. Furthermore, we detail how specific membrane signaling axes, including Eph receptors, Notch, and the SIRPα-CD47 checkpoint, alongside RIPK-mediated cell death pathways, govern endothelial dysfunction, macrophage polarization, and efferocytosis. We also discuss the contributions of UCP and ANGPTL proteins to cellular metabolism and inflammasome regulation. Notably, we propose an integrative perspective on cross-tier signaling crosstalk, highlighting complex feedback loops among histone deacetylases, KLFs, and Eph receptors that amplify vascular inflammation. Ultimately, comprehensively elucidating these immuno-vascular networks will pave the way for next-generation, precision-targeted therapies to mitigate the global burden of cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.